Macquarie Group LTD Glycomimetics Inc Transaction History

Macquarie Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.55 - $3.49 $4,944 - $6,767	1,939 New	1,939 $5,000
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $3,984 - $5,376	-400 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$13.7 - $17.12 $60,280 - $75,328	-4,400 Reduced 91.67%	400 $6,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $1.04 Million - $1.36 Million	-70,949 Reduced 93.66%	4,800 $77,000
Q1 2018 May 11, 2018	BUY	$16.06 - $25.35 $1.22 Million - $1.92 Million	75,749 New	75,749 $1.23 Million

25.6M

1.94M

153K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $8.91M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.